Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer: KOL Insight [2017]

Product Code:
596200874
Publication Date:
September 2017
Format:
PDF + PPTX
Price:
£6,795

Will new targeted therapies transform the treatment of colorectal cancer?

Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal cancer. But while Keytruda (pembrolizumab; Merck & Co.) and Opdivo (nivolumab; Bristol-Myers Squibb) represent the most recent additions to the CRC treatment armamentarium, do KOLs believe they’ll make an impact? An array of programmes are in late-stage development, including other PD-1/PD-L1 inhibitors, BRAF/MEK inhibitors, and cancer vaccines. All are vying for patients and the all-important seal of approval from key opinion leaders. But how will these products fare in a highly competitive space? And what will be the key to clinical and commercial differentiation? KOLs provide candid insights on these and other new therapies, their likely use, and how they’ll affect current mainstays such as anti-VEGFs and anti-EGFRs, in KOL Insight: Colorectal Cancer.

Ten North American and European KOLs provide their insight on 8 marketed/registered products, 7 pipeline programmes, 3 early-stage mechanisms of action and the potential for bevacizumab biosimilars.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • It’s about to get personal. As gene mapping becomes more common in the diagnosis of CRC, what impact will this have on treatment selection and sequencing of current and future treatment options?
  • Outlook unclear for checkpoint inhibitors. KOLs are split on whether these new additions will have a significant impact on CRC treatment outcomes. What could drive higher rates of adoption in the treatment algorithm?
  • New treatment guidelines on the horizon? Data on left side vs. right side tumours could usher in significant changes in the treatment algorithm for CRC. Do KOLs believe treatment guidelines will evolve, and what impact will this have on treatment selection?
  • Combination regimens to lead the charge. KOLs agree that combination regimens will become an increasingly important part of the CRC treatment algorithm in the near future. But which regimens are the best, and what clinical trials are needed to support their approval?
  • KOLs warming to bevacizumab biosimilars, but concerns still remain. With over a dozen Avastin biosimilars on the way, and one already approved in the US, KOLs are cautiously optimistic. What are their concerns, and what will biosimilars have to show to achieve widespread uptake?
  • The bar has been set, and it’s high. KOLs believe that novel therapies for CRC will be held to higher safety and efficacy standards in the future. How will this impact clinical development and investment in an area which still has significant levels of unmet need?
Request sample pages

Back to the top

Quotes

“Personally, I'm not 100 percent comfortable with that because with statistics you have to make some assumptions that things are close enough, but not exactly the same. When you say, ‘no clinically meaningful difference,’ that's in one tumour type and in one study. One study in lung cancer doesn't necessarily tell you that it's going to have the same [efficacy] in colon cancer.”
US Key Opinion Leader

 

“From a philosophical point of view, this is an interesting strategy. But I don't see the point to go in a Phase III trial, which is very costly and very difficult to run, when the Phase II trial is negative. What is the point? You should move to another target or modify something. I have worked on colorectal cancer for 15 years more or less. I have never seen any Phase II negative trial which converted into a positive Phase III trial, never in my life. I would not bet any money on this trial.”
European Key Opinion Leader

 


Sample of therapies covered

Marketed/Registered Therapies

  • Aflibercept (Zaltrap; Regeneron/Sanofi)
  • Bevacizumab (Avastin; Roche)
  • Ramucirumab (Cyramza; Eli Lilly)
  • Cetuximab (Erbitux; Eli Lilly/Merck Group)
  • Panitumumab (Vectibix; Amgen)
  • Regorafenib (Stivarga; Bayer)
  • Nivolumab (Opdivo; BMS)
  • Pembrolizumab (Keytruda; Merck & Co.)

Pipeline (P3) Therapies

  • Atezolizumab (Tecentriq; Roche)
  • Lefitolimod (Mologen)
  • Binimetinib (Array Biopharma/Pierre Fabre)
  • Cobimetinib (Cotellic; Exelixis)
  • Nintedanib (Boehringer Ingelheim)
  • Napabucasin (Boston Biomedical/Sumitomo Dainippon Pharma)
  • OncoVAX (Vaccinogen)

Early Stage MOAs (P1/P2)

  • Veliparib (ABT-888; AbbVie)
  • Entinostat (Syndax Pharmaceuticals)
  • SYM004 (futuximab/modotuximab; Symphogen)

KOLs interviewed

KOLs from North America

  • Johanna Bendell. Director of GI Cancer Research Program at Sarah Cannon Research Institute, Nashville, TN
  • Thomas Cartwright. Co-Chairman US Oncology Gastrointestinal Research, Ocala, FL
  • Mike Morse. Professor of Medicine, Professor in the Department of Surgery, Member of the Duke Cancer Institute, Duke University School of Medicine, Durham, NC
  • Bert O’Neil. Joseph W. and Jackie J. Cusick Professor of Oncology, Indiana University of Medicine, Indianapolis, IN
  • Bassel el-Rayes. Chief Clinical Research Scientist, Winship Cancer Institute, Emory University Hospital and Grady Memorial Hospital, Atlanta, GA

KOLs from Europe

  • Guiseppe Aprille. Department of Oncology, University Hospital, Udine, Italy
  • Khurum Khan. Locum Consultant GI and Acute Oncology, The Royal Marsden NHS Foundation Trust, Sutton, UK
  • Jaafar Bennouna. Professor, Medical Oncology, University of Nantes, France and Institut de Cancérologie de l’Ouest, Nantes, France
  • John Bridgewater. Clinical Researcher, University College London Cancer Institute, London, UK
  • Anonymous German KOL. Head of Oncology/Haematology Department, large teaching hospital in Germany

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved